SPRO Spero Therapeutics

Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024

Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024

CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its third quarter 2024 financial results and provide an update on its business on Thursday, November 14, after the market close. The Company does not intend to host a conference call.

About Spero Therapeutics

Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections. For more information -

Investor Relations Contact:

Shai Biran, PhD

Spero Therapeutics



Media Inquiries:



EN
07/11/2024

Underlying

SPROSpero Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Spero Therapeutics

 PRESS RELEASE
Free
SPRO Spero Therapeut...

Spero Therapeutics Provides Business Update and Announces Interim Lead...

Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes Esther Rajavelu Appointed Interim President and Chief Executive Officer, Frank Thomas Appointed Chairman of the Board Interim Changes to Leadership Follow the Company’s Response to a Wells Notice from the SEC Relating to Certain Public Disclosures Made in 2022 Phase 3 PIVOT-PO Trial of Tebipenem HBr Reaches Over 60% Enrollment as of December 31, 2024; Remains on Track to Complete Enrollment in 2H 2025 Cash Balance and Cash Runway Guidance Remains into mid-2026 CAMBRIDGE, Mass., Jan. 10, 2025 (...

January 10, 2025 1 EN
 PRESS RELEASE
Free
SPRO Spero Therapeut...

Spero Therapeutics Announces Third Quarter 2024 Operating Results and ...

Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025 Reiterate cash runway into mid-2026; Q3 2024 ending cash balance of $76.3M CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the third quarter e...

November 14, 2024 1 EN
 PRESS RELEASE
Free
SPRO Spero Therapeut...

Spero Therapeutics to Report Third Quarter 2024 Financial Results and ...

Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024 CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its third quarter 2024 financial results and provide an update on its business on Thursday, November 14, after the market close. The Company does not intend to...

November 7, 2024 1 EN
 PRESS RELEASE
Free
SPRO Spero Therapeut...

Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provi...

Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update Phase 2a proof-of-concept study of SPR720 for the treatment of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) did not meet its primary endpoint, based on planned interim analysis of 16 patients Phase 3 PIVOT-PO trial of tebipenem HBr remains on track for enrollment completion in 2H 2025 Cash runway extended into mid-2026 following a reduction in workforce and restructuring of operations; Unaudited Q3 2024 ending cash balance of $76.3M CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- ...

October 29, 2024 1 EN
 PRESS RELEASE
Free
SPRO Spero Therapeut...

Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of ...

Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024 In vitro data on SPR719 show low propensity for resistance development in NTM-PD MAC strains when administered as a single agent and in combination with standard of care agents Study highlighting SPR720 potential benefits for prolonged combination regimens typical to NTM-PD treatment CAMBRIDGE, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharm...

October 16, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch